• Login
    • Join
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Exclusives
    • Manufacturing
    • Markets
    • Top 10
    • Buyers' Guide
    • Events
    • Microsites
    • More
  • Magazine
  • News
  • Exclusives
  • Manufacturing
  • Markets
  • Top 10
  • Buyers' Guide
  • Events
  • Microsites
  • Current & Past Issues
    Features
    Departments
    Columns
    Editorial
    Digital Edition
    Subscribe Now
    Advertise Now
    Editorial Guidelines
    eNewsletter Archive
    Top Features
    Instrumentation Innovations: A Review of Instrument Manufacturing

    The Total Package: Packaging and Sterilization for Orthopedics

    Helping Nature Take Its Course: A Biologics Breakdown

    Making the Grade: Orthopedic Materials Spotlight

    Mending Mishaps: A Trauma Technology Overview
    Breaking News
    Certifications
    Clinical Trials
    Device Approvals & Patents
    Financial & Deals
    International
    Market Data & Trends
    OEM News
    Orthopedic Innovators
    People
    Product & Service Releases
    Products
    Quality, Recalls & Risk
    Regulatory & Legal
    Supplier & Contract Mfg.
    Live From Shows
    Top News & Features
    Lincotek Medical Expands Coatings and Additive Capacity

    Spinal Elements Relaunches the Luna XD and Orbit Systems

    Coronavirus Triggers Double-Digit Revenue Dropoff at Smith+Nephew

    FDA Approves Accufix Surgical's Accu-Joint Hemi Implant

    FDA OKs Q-Collar Device to Protect Athletes’ Brains During Head Impacts
    3-D Printing/Additive Mfg.
    Assembly & Automation
    Biocompatibility & Testing
    Clean Room
    Coatings/Surface Modification
    Contract Manufacturing
    Design
    Extrusion
    Finishing
    Forging & Casting
    Instruments, Cases & Trays
    International/Offshoring
    Laser Processing
    Materials
    Machining & Tooling
    Molding
    Packaging & Sterilization
    Prototyping
    Research & Developement
    Software & Quality
    Staffing, Training & Prof. Dev.
    Supply Chain

    Medtech Matters: FDA’s Ambiguity on Hyaluronic Acid

    Orthopedic Innovators: Optimizing the Contract Services Experience

    Fusion Robotics Receives FDA Clearance for Spinal Navigation and Robotics System

    First Implantation of CTL Amedica's Minimally Invasive Flex Tower

    NuVasive Nabs Simplify Medical for $150M
    Biologics
    Bracing/Prosthetics
    Extremities
    Imaging
    Instruments
    Large Joint
    MIS/Robotics
    Spine/Neurology
    Trauma/Sports
    Top Markets
    Orthopedic Solutions from Man’s Best Friend

    The FDA’s Flip-Flop on Hyaluronic Acid

    HSS, Zimmer Biomet's Solution for the Episode of Orthopedic Care

    Rising to the Challenge: Q&A with AAOS Second VP Dr. Savoie

    Teleconferencing in the OR
    Companies
    Categories
    Company Capabilities
    White Papers
    Add New Company
    International Buyers Guide Companies
    Edge International/Supra Alloys

    ARCH Medical Solutions

    Carpenter Technology

    Lyons

    WuXi AppTec
    Industry Events
    Webinars
    • Magazine
      • Current & Past Issues
      • Features
      • Editorial
      • Departments
      • Columns
      • Digital Edition
      • eNewsletter Archive
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
    • Breaking News
    • Buyers' Guide
      • Companies
      • Categories
      • Company Capabilities
      • White Papers
      • Add Your Company
    • Manufacturing
      • 3-D Printing/Additive Mfg.
      • Assembly & Automation
      • Biocompatibility & Testing
      • Clean Room
      • Coatings/Surface Modification
      • Contract Manufacturing
      • Design
      • Extrusion
      • Finishing
      • Forging & Casting
      • Instruments, Cases & Trays
      • International/Offshoring
      • Laser Processing
      • Materials
      • Machining & Tooling
      • Molding
      • Packaging & Sterilization
      • Prototyping
      • Research & Developement
      • Software & Quality
      • Staffing, Training & Prof. Dev.
      • Supply Chain
    • Markets
      • Biologics
      • Bracing/Prosthetics
      • Extremities
      • Imaging
      • Instruments
      • Large Joint
      • MIS/Robotics
      • Spine/Neurology
      • Trauma/Sports
    • Top 10
    • Online Exclusives
    • Slideshows
    • Videos
    • Webinars
    • Events
      • Industry Events
    • Live from Show Event
    • About Us
      • About Us
      • Contact Us
      • Privacy Policy
      • Terms of Use
      • Advertise With Us
    Online Exclusives

    The FDA’s Flip-Flop on Hyaluronic Acid

    Offering an introduction to this treatment modality for osteoarthritis, this article also looks at recent changes at FDA.

    The FDA’s Flip-Flop on Hyaluronic Acid
    Related CONTENT
    • Lincotek Medical Expands Coatings and Additive Capacity
    • Spinal Elements Relaunches the Luna XD and Orbit Systems
    • FDA OKs Q-Collar Device to Protect Athletes’ Brains During Head Impacts
    • Medtech Matters: FDA’s Ambiguity on Hyaluronic Acid
    • Align Technology Inc. Executive Joins Zimmer Biomet Board
    Mike Daley, CEO, OrthogenRx02.10.21
    Osteoarthritis (OA) is a degenerative disease of the synovial joints, which causes joint pain and functional impairment. It occurs frequently in adults over 50 years old and is a major cause of disability worldwide. OA is a progressive disorder, primarily affecting the cartilage found on the ends of bones in joints, with different degrees of disease severity that requires long-term management.
     
    Over the course of the disease, various options are available to treat the symptoms including non-pharmacologic, pharmacologic, and surgical treatment regimes. In the absence of a cure for OA, there are multiple systemic, oral medications available over-the-counter and by prescription that are commonly used to manage the pain associated with OA. These can include acetaminophen (Tylenol), opioids (Tramadol, Oxycontin, etc.), and non-steroidal anti-inflammatory drugs (NSAIDs; Advil, Aleve, Celebrex, etc.). When administered over a long time for a chronic condition like OA, however, many of these result in significant heart and intestinal toxicity (FDA mandated Black Box Warnings), or addiction issues, especially in patients with other underlying conditions (co-morbidities) that can place these patients at particularly serious risk.
     
    There are also two approved treatments delivered locally by direct injection into the knee joint that can avert many of the drawbacks of the orally administered systemic treatments. These are intra-articular corticosteroid (steroids) and hyaluronic acid (HA) injections. In a recent meta-analysis sponsored by the Agency for Healthcare Research and Quality (AHRQ), an agency of the U.S. Department of Health and Human Services, comparing various treatment options for OA knee pain, intra-articular injections (steroids and HAs) were found to have two to three times greater clinical effect size and less adverse reactions. While steroids generally only require a single injection, their duration of effectiveness (pain relief) is generally limited to four to six weeks. In addition, there is some evidence that frequent and chronic use of steroids may exacerbate the degradative process of cartilage and exacerbate OA disease progression, so their judicious clinical use is recommended.
     
    In contrast, intra-articular HAs require one, three, or five weekly injections, but their clinical benefit tends to last six months or longer, and with minimal side effects. They also have no known drug interactions that could create a clinical concern (OA treatment populations commonly take multiple medications for other conditions). Interestingly, despite this compelling data in favor of intra-articular HA therapy, the American Academy of Orthopedic Surgeons (AAOS) and the American College of Rheumatologists (ACR) have not recommended their use. This is in contrast to most international organizations [Osteoarthritis Research Society International (OARSI), European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), and European League Against Rheumatism (EULAR)], which have offered a limited endorsement or fully endorsed the use of intra-articular HAs for the treatment of OA knee pain, especially in patients with multiple comorbidities. Based upon the literature, the negative recommendations are more related to interpretation of the proper negative controls rather than the significant improvement in pain observed in clinical studies.
     
    HA and OA Knee Pain
    HA is a glycosaminoglycan, or polymer of a simple disaccharide (N-acetyl-D glucosamine and glucuronic acid) found throughout the body, but in especially high concentrations in the synovial fluid of articular joints, like the knee. As a solution, HA exhibits unique physical properties of viscosity and elasticity (viscoelastic) that assists in joint lubrication, resistance to compression, and shear forces. One of the signs of OA is a decrease in the concentration of HA, as well as a breakdown of the size of the HA polymer (molecular weight). It is believed this change is associated with the elicitation of the clinical symptoms of OA—pain and joint stiffness.
     
    Injection of HA into the joint helps to restore the synovial fluid lubrication and cushioning properties, consequently improving joint biomechanics. A treatment course of intra-articular HA therapy may last for six months or more, and some insurance claims data suggests it may even facilitate long-term benefits, but these observations on HA treatment modifying disease progression require further investigation. In addition, some health insurance claims data suggests HA treatment may reduce the reliance on oral pain medications, including opioids.
     
    Is HA a Device or a Drug?
    Both, it would seem, according to the FDA, which is where the problem lies.
     
    Globally, intra-articular injections of HA have been adopted as a common, standard-of-care, non-surgical treatment for OA knee pain. The approved indications are for patients who have failed to respond adequately to conservative nonpharmacologic therapy (e.g., weight loss, exercise, or physical therapy) or over-the-counter analgesics (simple analgesics or NSAIDs). In 1997, the U.S. Food and Drug Administration (FDA), through a formal process called a Request for Designation (RFD), determined that how the product mediated its primary action (i.e., pain relief) was through mechanical means (i.e., lubrication, cushioning, and resistance to shear) as opposed to a substance (other than food) intended to affect the structure or any function of the body. Therefore, HAs were to be regulated as a Class III medical device. Patients treated with intra-articular HA injections who receive six months or more of pain relief may be safely retreated every six months. As previously stated, the HA class has an outstanding safety profile even upon retreatment, with no product-associated deaths recorded and no known interactions with other systemic medications. This safety profile is in strong contrast to many of the standard-of-care oral pain medications often used for OA knee pain. It should be further stated that since the product must be administered by a healthcare professional, there are no issues regarding over-dosing or compliance.
     
    This 33-year global (Japan and Italy, 1987) and 23-year (U.S. FDA, 1997) history of safety and efficacy with a consistent regulatory approval process for HA products was placed in serious jeopardy on December 18, 2018. On that date, without any prior public notice, plan for a staged implementation of the policy, nor clarity in the process, the FDA issued a Notice in the Federal Register (NFR) stating the FDA “believes that intra-articular HA products may be acting as drugs rather than devices.” With a further lack of clarity, they “suggested” companies contemplating a submission “are encouraged to obtain an informal or formal classification and jurisdiction determination”—a request to the Office of Combination Products for a RFD.
     
    Interestingly, dating back to 1993, the Agency has consistently determined on at least five separate occasions that these HA products are Class III medical devices. Although the Notice stated sponsors are merely “encouraged” to obtain jurisdictional review, this NFR has become a de facto policy of the FDA, and subsequently, CDRH will no longer accept pre-market approval (PMA) applications for new HA products that have not undergone such RFD review.
     
    Also, in the two years prior to the NFR, four intra-articular HA products had been submitted and approved, and yet, in the two years following the Notice, not a single intra-articular IAHA product has been approved. The net effect will be less competition and no innovation in products because of this significant and uncertain regulatory pathway. The manufacturers of existing products are also in a quandary because the future status of the 16 IAHA products is unknown. Are they devices or drugs?
     
    Moving forward, even “like products” that are essentially equivalent in composition, dosage form, and formulation will be regulated differently—a clear violation of FDA administrative law. This action was taken without provocation for the safety or effectiveness of the product class. It was taken without new scientific data (FDA references were primarily reviews with primary sources dating back prior to 2005). Furthermore, this new policy regarding intra-articular HA products does not comport with the legal requirement in administrative law—5 U.S.C. § 706 (2)(A)—that like products be treated alike, and the procedures for implementing a policy change without advance notice raises serious concerns over the foundation of device development programs that may not be predictable and could be far reaching. Device or even drug companies will be challenged to find financing to advance their technology in the face of uncertain regulatory pathway.
     
    Consequences of Inconsistent Regulatory Reviews
    The underpinnings of device innovation and product development require a clear and predictable approval pathway. This is especially the case for Class III medical devices and drugs or biologics that require randomized controlled clinical studies to obtain regulatory approval and may take a decade to complete at a cost of 100s of millions of dollars. This significant FDA policy change without prior notice may mark a sea-change in the Agency signaling that they plan on future declarations without due process or public hearings for comment, and an ill-defined implementation process. The challenges of investing in healthcare companies is significant and no investor will find such uncertainty an acceptable level of risk for a financial commitment thus putting at jeopardy the very fuel that drives the biopharmaceutical/medical technology engine of innovation.
     
    This action by the FDA begs the question, “What’s next?” Will they reconsider decisions on absorbable biomaterials, stents, devices that require integration with surrounding tissues, drugs or biologics that may exhibit unique physical properties? This misguided lack of adherence to established processes must stop, and the Agency needs to reflect and implement judicious and well-planned processes as defined by the law to govern product oversight before they effectively disrupt the device and some segments of the drug innovation pipeline.
    Suggested For You
    Lincotek Medical Expands Coatings and Additive Capacity Lincotek Medical Expands Coatings and Additive Capacity
    Spinal Elements Relaunches the Luna XD and Orbit Systems Spinal Elements Relaunches the Luna XD and Orbit Systems
    FDA OKs Q-Collar Device to Protect Athletes’ Brains During Head Impacts FDA OKs Q-Collar Device to Protect Athletes’ Brains During Head Impacts
    Medtech Matters: FDA’s Ambiguity on Hyaluronic Acid Medtech Matters: FDA’s Ambiguity on Hyaluronic Acid
    Align Technology Inc. Executive Joins Zimmer Biomet Board Align Technology Inc. Executive Joins Zimmer Biomet Board
    Orthopedic Innovators: Optimizing the Contract Services Experience Orthopedic Innovators: Optimizing the Contract Services Experience
    Pandemic Pain: NuVasive Pandemic Pain: NuVasive's 2020 Sales Fall 10 Percent
    Fusion Robotics Receives FDA Clearance for Spinal Navigation and Robotics System Fusion Robotics Receives FDA Clearance for Spinal Navigation and Robotics System
    Kaia Health Unveils Next-Gen Complete MSK Care Solutions Kaia Health Unveils Next-Gen Complete MSK Care Solutions
    First Implantation of CTL Amedica First Implantation of CTL Amedica's Minimally Invasive Flex Tower
    NuVasive Nabs Simplify Medical for $150M NuVasive Nabs Simplify Medical for $150M
    FDA OKs Brainlab FDA OKs Brainlab's Loop-X Mobile Imaging Robot, Cirq Robotic Alignment Module
    UConn Professor Recognized for Bone Regenerative Engineering Research UConn Professor Recognized for Bone Regenerative Engineering Research
    Washington University Professor Honored for Functional Cartilage Engineering Research Washington University Professor Honored for Functional Cartilage Engineering Research
    Ranfac, Endocellutions Form Cervos Medical Ranfac, Endocellutions Form Cervos Medical

    Related Online Exclusives

    • Large Joint
      Orthopedic Solutions from Man’s Best Friend

      Orthopedic Solutions from Man’s Best Friend

      One company wants to turn an innovation from veterinary medicine into a better quality of life for human patients.
      Marc Knebel, Global Segment Head Medical Systems—Head of VESTAKEEP Europe bei Evonik Operations GmbH 02.11.21

    • Software & Quality
      HSS, Zimmer Biomet

      HSS, Zimmer Biomet's Solution for the Episode of Orthopedic Care

      Zimmer Biomet exec Ivan Tornos provides insight into merging mymobility virtual care with HSS Orthopedic Care Pathways.
      Sam Brusco, Associate Editor 01.05.21

    • Rising to the Challenge: Q&A with AAOS Second VP Dr. Savoie

      Rising to the Challenge: Q&A with AAOS Second VP Dr. Savoie

      Orthopedic surgeons sidelined by the COVID-19 pandemic found ways to serve patients and healthcare this year as the virus spread.
      Michael Barbella, Managing Editor 12.14.20


    • Large Joint
      Teleconferencing in the OR

      Teleconferencing in the OR

      An audio/video solution enables medical device reps to still make appearances in the OR to support surgeons and healthcare providers.
      Sean Fenske, Editor-in-Chief 10.29.20

    • 3-D Printing/Additive Mfg.
      Material Advantage: How Additive Manufacturing Can Revolutionize Orthopedics

      Material Advantage: How Additive Manufacturing Can Revolutionize Orthopedics

      The technology enables innovations for both surgical tools and orthopedic implants.
      Katherine Rundell, Medical Writer, Academized 10.06.20

    • Market Conditions Ripe for Robotics Growth

      Market Conditions Ripe for Robotics Growth

      The world's aging, longer-living population and better clinical data will help drive expansion in the decade ahead.
      Michael Barbella 10.05.20


    • Machining & Tooling
      Valuating Used CNC Machines

      Valuating Used CNC Machines

      There are factors to consider to ensure the seller gets the most money from a used equipment sale.
      Michael Dunlop, Technical Writer 09.29.20

    • Robots Can Help Improve TLIF Procedure Accuracy

      Robots Can Help Improve TLIF Procedure Accuracy

      The surgery's success is dependent upon the accuracy of pedicle screw placement as determined by pre-operative planning.
      Richard V. Chua, M.D., FAANS, FACS, Northwest NeuroSpecialists PLLC and professor, Department of Neurosurgery, University of Arizona College of Medicine 09.24.20

    • 3-D Printing/Additive Mfg.
      Additive-Manufactured Orthopedic Implants Under MDR

      Additive-Manufactured Orthopedic Implants Under MDR

      Orthopedic device manufacturers have specific considerations to keep in mind when using AM under the upcoming EU regulatory system.
      Dr. Max Singh, Simon Schlagintweit, and Gregor Reischle—TÜV SÜD 08.11.20


    • Biologics
      Academia: The Main Innovation Source for Orthobiologics

      Academia: The Main Innovation Source for Orthobiologics

      Smith+Nephew has formed a Biologics and Regenerative Medicine R&D team dedicated to development of innovative orthobiologic products.
      Michael Barbella, Managing Editor 06.05.20

    • Biologics
      Surgeon Creativity Shaping Orthobiologics Innovation

      Surgeon Creativity Shaping Orthobiologics Innovation

      Good relationships with surgeon customers can lead to collaborative development efforts.
      Michael Barbella, Managing Editor 05.29.20

    • Spine/Neurology
      Reducing the Footprint of Spinal Fusion

      Reducing the Footprint of Spinal Fusion

      This interview with Neo Medical’s CEO reveals the firm’s strategy to refresh the view of spinal surgery instrumentation and technology.
      Sean Fenske, Editor-in-Chief 05.29.20


    • 3-D Printing/Additive Mfg.
      5 Ways 3D Printing Will Change Medtech

      5 Ways 3D Printing Will Change Medtech

      Orthopedic-related devices such as prosthetics and instrumentation stand to benefit from the technology.
      Joshua McAlpin, Medical Industry Consultant 03.27.20

    • An Elected Sacrifice in COVID-19

      An Elected Sacrifice in COVID-19's Wake

      Patients with scheduled orthopedic surgeries are cancelling procedures to help stem the further spread of the virus.
      Michael Barbella, Managing Editor 03.26.20

    • 3-D Printing/Additive Mfg. | Machining & Tooling
      Improving the Speed to First Part: A Case Study

      Improving the Speed to First Part: A Case Study

      An orthopedic device contract manufacturer uses multi-axis CNC mill turn machines and CAM software to maintain a competitive edge.
      Israel Klain, Director, GibbsCAM Software, 3D Systems 03.26.20


    Trending
    • FDA Approves Accufix Surgical's Accu-Joint Hemi Implant
    • Mini MRI For Hand And Wrist Imaging Can Be Used Nearly Anywhere
    • Cementless Hip Implants Are Gradually Losing Their Popularity In Europe
    • OrthoPediatrics Expands Agent Network In Three European Countries
    • Coronavirus Triggers Double-Digit Revenue Dropoff At Smith+Nephew
    Breaking News
    • Lincotek Medical Expands Coatings and Additive Capacity
    • Spinal Elements Relaunches the Luna XD and Orbit Systems
    • Coronavirus Triggers Double-Digit Revenue Dropoff at Smith+Nephew
    • FDA Approves Accufix Surgical's Accu-Joint Hemi Implant
    • FDA OKs Q-Collar Device to Protect Athletes’ Brains During Head Impacts
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • Instrumentation Innovations: A Review of Instrument Manufacturing
    • The Total Package: Packaging and Sterilization for Orthopedics
    • Helping Nature Take Its Course: A Biologics Breakdown
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Preclinical Trial Suggests Fish Hydrolysate Attenuates Neuroinflammation Greater than DHA Alone
    Study Explains Link Between Probiotic Strains and Children’s Immune Health Benefits
    Maypro Launches Brain Heatlh Ingredient NeuroHD
    Coatings World

    Latest Breaking News From Coatings World

    Chromaflo Technologies Adds Benjamin Woeste as Territory Sales Manager
    Matt Fogel Named Mule-Hide's Territory Manager – Southern Virginia
    Benjamin Moore Launches COMMAND
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Plastikos Medical Begins Phase II of Expansion
    Ready Robotics Hires Proven Automation Leaders
    Philips, Disney Join Forces to Reduce Childrens' MRI Anxiety
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Innoforce and dMed Enter Development Collaboration
    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    Four Female Leaders Appointed to Cell & Gene CDMO
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    BizBash Names Unfiltered Experience ‘People's Choice: Best Influencer Event’
    P&G Makes Progress Toward Packaging Circularity in Europe
    Coty Partners with LanzaTech to Introduce Sustainable Ethanol
    Happi

    Latest Breaking News From Happi

    Coty Partners with LanzaTech to Reduce Its Environmental Impact
    Waterless Beauty, Simplified Routines Shape Clean Beauty at Whole Foods
    Redken Updates Packaging, Adds New Products
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Fort Dearborn Company acquires Hammer Packaging
    Ashland announces PSA price hike in North America
    Arrow Systems and Sihl form flexible packaging partnership
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Joa Announces Expandable Absorbent Core Wrap Solution
    Principle Business Enterprises Celebrates 60 Years
    Mann+Hummel Invests in Pamlico Air
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Lincotek Medical Expands Coatings and Additive Capacity
    Spinal Elements Relaunches the Luna XD and Orbit Systems
    Coronavirus Triggers Double-Digit Revenue Dropoff at Smith+Nephew
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login